Social & Behavioral Health Faculty Publications

Social & Behavioral Health

11-18-2021

The Role of Vitamin E in Slowing Down Mild Cognitive
Impairment: A Narrative Review
Ram Lakhan
Berea College

Manoj Sharma
University of Nevada, Las Vegas, manoj.sharma@unlv.edu

Kavita Batra
University of Nevada, Las Vegas, kavita.batra@unlv.edu

Frazier B. Beatty
Regis College, Weston

Follow this and additional works at: https://digitalscholarship.unlv.edu/socbeh_fac_articles
Part of the Cognitive Neuroscience Commons

Repository Citation
Lakhan, R., Sharma, M., Batra, K., Beatty, F. (2021). The Role of Vitamin E in Slowing Down Mild Cognitive
Impairment: A Narrative Review. Healthcare, 9(11), 1-12.
Available at: http://dx.doi.org/10.3390/healthcare9111573

This Article is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV
with permission from the rights-holder(s). You are free to use this Article in any way that is permitted by the
copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from
the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/
or on the work itself.
This Article has been accepted for inclusion in Social & Behavioral Health Faculty Publications by an authorized
administrator of Digital Scholarship@UNLV. For more information, please contact digitalscholarship@unlv.edu.

healthcare
Review

The Role of Vitamin E in Slowing Down Mild Cognitive
Impairment: A Narrative Review
Ram Lakhan 1 , Manoj Sharma 2 , Kavita Batra 3, *
1
2

3
4

*

and Frazier B. Beatty 4

Department of Health and Human Performance, Berea College, Berea, KY 40404, USA; Lakhanr@berea.edu
Department of Social & Behavioral Health, School of Public Health, University of Nevada,
Las Vegas, NV 89119, USA; manoj.sharma@unlv.edu
Office of Research, Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, NV 89102, USA
Graduate Department of Public Health, School of Health Sciences, Regis College, Weston, MA 02493, USA;
frazier.beatty@regiscollege.edu
Correspondence: kavita.batra@unlv.edu

healthcare9111573

Abstract: With the aging population, dementia emerges as a public health concern. In 2012, the
Health and Retirement Study found that 8.8% of adults over 65 years suffered from dementia. The
etiopathogenesis and treatment of dementia are not well understood. Antioxidant properties of
Vitamin E and its major elements tocopherols and tocotrienols have been reported to be effective
in slowing down the progression of dementia from its initial stage of Mild cognitive impairment
(MCI). Therefore, the current review aims to explore the role of vitamin E on MCI. A literature
search using the key words “Vitamin E, tocopherols, tocotrienols, and mild cognitive impairment”
was conducted in MEDLINE (PubMed), CINAHL, and Google Scholar. The inclusion criteria were:
(1) articles published in the past ten years; (2) published in English language; (3) published in
peer-reviewed journals; and (4) descriptive and epidemiological or evaluation studies. Articles
published prior to 2010, focused on other forms of dementia than MCI, grey literature and non-peerreviewed articles were excluded. A total of 22 studies were included in the narrative synthesis. The
results were equivocal. Eleven studies showed some level of the neuroprotective effect of Vitamin E,
tocopherols and tocotrienols on the progression of MCI. The mixed results of this review suggest
further exploration of the possible protective effects of Vitamin E on the development of dementia.
Future studies can be conducted to decipher antioxidant properties of vitamin E and its association
with slowing down the cognitive decline.
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1. Introduction
Dementia is a serious public health concern with nearly 50 million people having
some form of dementia globally [1]. Reportedly, about 60% of the dementia population live
in low and middle-income countries (LMICs) [1]. Estimates suggest that about 10 million
people get dementia every year and about 15–20% of elderly population reported having
mild cognitive impairment (MCI) as the early stage of dementia [1–3]. MCI causes a
slight but observable and measurable decline in the memory and thinking skills of an
individual. In some individuals, MCI can be reversible (if physiological in origin), however,
the likelihood of the reversal to the normal cognitive capability is less for majority of people
if it is pathological [2,3]. With due course, MCI advances to the next stage with nearly 65%
of people developing more severe forms [2,3].
According to the previous meta-analytical evidence presented by the American
Academy of Neurology, the prevalence of MCI was nearly 7% among people with age
60–64 years, which increases with advancing age [3,4]. In the United States (U.S.), the
highest prevalence was reported among elderly above 75 years of age [4]. These trends
are not only limited to developed countries, low- and middle-income countries indicate
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similar patterns [5]. However, due to lack of population-based studies, the true estimates
are unavailable. According to the previous reports, the prevalence of MCI ranged from
4.5% to 15.4% among South Asian countries [6–9]. Differences in MCI by demographic
characteristics (e.g., gender, race/ethnicity, education) were also noted with women being
at greater lifetime risk for dementia compared to their male counterparts [10–12]. The
occurrence of MCI is found delayed and lenient towards the end of life among whites
and highly educated people while the onset of MCI is observed at younger age among
blacks and those with lower education attainment [10–12]. The lifetime risk of dementia
is 21% among men with an associate degree while it is 35% for those who have less than
high school education [10–12]. White women have a shorter cognitively impaired life
compared to black women (6 years vs. 12 to 13 years) [10–12]. The burden of dementia
further translates into higher cost associated with its management [2]. According to the
Alzheimer association, through identification of early stages of Alzheimer disease (AD) i.e.,
MCI, nearly $7 to $7.9 trillion in health and long-term care can be saved [2].
MCI has severe implications for the patients and their family members and challenges
are multifactorial in origin [13]. Often time patients and their family members are unable
to identify cognitive decline at earlier stages, particularly in older population groups, in
whom cognitive decline is a normal physiological phenomenon. Moreover, cooccurrence of
other age-associated diseases are likely to occur in this group with a limited ability to make
a differential diagnosis [14,15]. Cognitive insufficiency impacts the quality of life, individual’s functioning, their relationship with the family members, and their self-esteem [14,15].
Caregivers experience high level of caregiving burden for the larger population of MCI [16].
Given the unavailability of medication to treat, prevent, or slow the progression of MCI to
dementia, preventive strategies take precedence for at-risk population groups to prevent
progressive deficits [17]. Prevention of somatic diseases, promotion of physical and mental
exercise, cognitive training, avoidance of toxins, reduction in stress, stopping smoking, and
use of dietary compounds such as antioxidants and supplements are some of the suggested
to address MCI [17,18]. Among antioxidants, vitamins play a critical role in reducing or
delaying to the process of cognitive decline in people with MCI. Among all vitamins, vitamin E was found to be effective in reducing MCI [17–23]. Vitamin E is a fat-soluble vitamin
and found in variety of foods [19]. Its usable form (i.e., alpha tocopherol) is considered a
scavenger of free radicals in the body [19], which controls brain prostaglandin synthesis
and regulates nucleic acid synthesis. While some studies have documented association of
vitamin E intake in slowing down the progression of MCI, collective evidence to investigate
its significance is still lacking [17–23]. Therefore, the purpose of this study was to review
existing literature to decipher role of vitamin E in slowing down MCI progression.
2. Methods
2.1. Search Strategy
Bibliographical databases, including Medline (PubMed), CINAHL, and Google Scholar
were quickly searched in January/February 2020. Pharmacological synonyms of vitamin
E were used as related terms to locate potential evidence to be included in this review.
Articles related to cognitive impairment were also sought using the Boolean operator
“AND” to narrow down search results to include articles containing the specified terms. A
detailed list of key words is shown in Table 1.
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Table 1. List of keywords used for literature search.
Main Term

Related Terms Used

Vitamin E

Tocopherol * OR D1 alpha tocopherol OR Preventive
therapy OR tocotrienols OR Aquasol E OR Antioxidant

Mild cognitive impairment

Dementia OR Alzheimer’s disease OR Cognitive decline OR
Amentia OR Mental disorder OR Paranoid Dementia OR
Senile Paranoid

AND

2.2. Inclusion Criteria and Data Abstraction
The inclusion criteria of this review were the following; (1) observational, randomized
controlled trials, clinical and laboratory studies published over past ten years; (2) studies
published in English language; (3) published in peer-reviewed journals; and (4) descriptive
and epidemiological or evaluation-based studies. The exploration of preventive relationship of vitamin E with mild cognitive impairment is relatively new. Therefore, we selected
to assign a broad range of criteria including human and animals-based studies published
in the 10 years of timeframe. Articles published before 2010, focused on other forms of
dementia than MCI, grey literature, abstracts—only studies, and non-peer-reviewed articles
were excluded. We also conducted a post-hoc search in July 2021 to update our literature
matrix used for this review. Details about the search results were saved in the spreadsheet
by the lead author. Titles and abstracts were screened for relevancy and eligibility. If found
relevant, full-texts were read thoroughly and data were extracted in a standardized data
collection form. Variables such as year of publication, study type, outcomes, key findings,
neuroprotective role of vitamin E, and conclusions were tabulated in the data collection
form.
3. Results
Following keyword search, 53 articles in Medline/PubMed/Google Scholar and 5 in
CINAHL database were found. Out of those, 48 studies met the inclusion criteria. Abstracts
of all 48 studies were screened. Twenty-six studies were excluded for variety of reasons
of being editorials, commentaries/letters, abstract-only study, combined vitamin E with
other vitamins, focused on other form of dementia rather than MCI, reviews, narratives
and opinion-based papers. Finally, 22 papers [19–41] were included in this review for the
data summarization (Figure 1). Characteristics of finally included studies are provided in
Table A1 in Appendix A.
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4. Discussion
The purpose of this review was to examine the effect of Vitamin E in slowing down
cognitive decline in MCI. Some evidence from our literature synthesis points to the putative role of Vitamin E in slowing down MCI progression to dementia. Overall, the review
collectively demonstrated through analysis of various experimental studies in rats, mice,
and animals and cross-sectional, case-control, prospective cohort, experimental, clinical,
and double-blind randomized in human that Vitamin E has some neuroprotective effect
in slowing down progression to dementia. One clinical study carried out to lower the
effect of cisplatin chemotherapy neurotoxicity, the supplementation with vitamin E (alpha
tocopherol) has shown lower level of neurotoxicity, which indicates that vitamin E plays a
neuroprotective role [42] even when the cause of neurotoxicity could be other than mild
cognitive impairment. The findings of Gugliandolo et al. (2017) have reported similar physiological responses of Vitamin E on MCI [43–45]. Another study by Kaneai et al., indicated
that vitamin E offers some neuroprotective benefits by improving neurotransmission [45].
Presently, no medication can treat, prevent, or slow the progression of MCI to dementia.
However, it is important to explore the role of vitamins and antioxidants in reducing or
delaying to the process of cognitive decline in people with MCI [17]. Studies show that
high plasma Vitamin E levels have been associated with better cognitive performance in
both ageing populations, dementia, and AD patients [42,43].
Consistent to previous studies it is understood that Vitamin E might have some
therapeutic role when it comes to MCI and its progression to dementia. Since several
studies in human as well as in rats and mice were MCI associated with lower level of
tocopherol. Thus, it may be considered a good practice to maintain Vitamin E level through
dietary sources. Vitamin E can also lead to toxicity that can be fatal in some cases which
warrants careful monitoring of its levels in the aging population. The guidelines on the
safe dose of vitamin E varies from 800–2000 IU/day as reported by previous studies [46,47].
Therefore, these findings should be considered rather carefully to prevent any toxic effects
of vitamin E. In the meanwhile, more randomized controlled trials to further elucidate
the role of Vitamin E on MCI must be conducted with larger sample sizes. Even though
there are mixed results they favor a potential neuroprotective effect of Vitamin E in MCI. It
would be recommended for clinical practice that the Vitamin E levels be checked annually
in the elderly, and they should be provided Vitamin E supplementation in maintaining its
adequate level.
Limitations
This review has certain limitations including that research articles focused on dementia, which have explored relationship of vitamin E on mild cognitive impairment but not
necessarily mentioned MCI in the title or abstract, those articles might have left from inclusion. Authors utilized phrase searching, however, due to the lack of truncation rules for
some terms of dementia, some articles might have been missed. Therefore, future studies
using a systematic literature review with a well-defined and peer-reviewed search strategy
can be conducted. Six animal studies are included in this review and comparison were
made between findings in human and animals. Comparison of effect of an element between
human and animal specially on cognitive function and process is extremely complex. In
simpler terms, behavioral studies to investigate cognitive decline among humans offer
higher inferential benefits than those being conducted among animals due to differences in
their baseline intelligence levels and capabilities. Next, studies included in this review were
heterogenous in terms of type of measures used to detect the cognitive decline and these
measures had varied threshold criteria. These restricted our ability to generate pooled
estimates, which otherwise might have helped us to quantify the association between
vitamin E and neuroprotection in the form of appropriate effect sizes (such as odds ratios).
In addition, understanding trajectories of change in cognitive function will be difficult with
such a heterogeneity. On the other hand, the observation of physiological process relatively
easier in animal population compared to human due to ethical consideration. The findings
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of animal studies showing favorable outcome of vitamin E on cognition process may not
be rewarding when compared to human. The database such as LILACS were not explored.
Few studies included in this review has a very small sample size or their results were
mixed up with some other compound which might have impacted on the conclusion of
this review.
Despite the limitations, the study has implications for practice. Vitamin E supplementation should be monitored closely when in combination with Vitamin E nutrients from
food sources. Other than alpha tocopherol, no other component of vitamin was found
helpful in slowing the process of cognitive decline. It is not known if the other form of
vitamin E or its component has negative effect on cognitive process. Therefore, caution
needs to be practiced in optimizing level of vitamin E that way the other components of
vitamin E do not affect the properties of alpha tocopherol and its impact on MCI. In addition, this review indicates favorable physiological and neurochemical benefits of vitamin
E in protecting or delaying cognitive decline process, however, effects may be different
among animals and human-beings. These differences may be due to the varied vitamin
E requirements and physiological mechanisms among these groups. Therefore, further
research to understand associations between vitamin E requirements, consumption, and
effects at organismal levels would be critical to unfold interactions of vitamin E with body
mechanisms.
5. Conclusions
In conclusion, epidemiological, clinical, nor other studies have provided the conclusive
answer to whether or not Vitamin E slows the progression of MCI. Further research with
human subjects is needed to understand the safety and efficacy of Vitamin E as a nutritional
supplement to promote health ageing. Future research to understand the physiological
process of alpha tocopherol on cognitive process in human beings can be conducted.
Author Contributions: Conceptualization, R.L. and M.S.; methodology, R.L., M.S., K.B.; software,
R.L., K.B.; validation, K.B., F.B.B., M.S.; data curation, R.L.; writing—original draft preparation, R.L.,
M.S., K.B., F.B.B.; writing—review and editing, K.B., F.B.B.; visualization, R.L., K.B.; project administration, R.L., M.S. All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest.

Appendix A
Table A1. Reviewed studies and their salient findings (n = 22).
Authors

Wu et al.

Huang
et al.

Year

2010

2010

Study Type

Sample Characteristics

Findings

Experimental
study in rats

Rats were fed 500 IU/Kg
Vitamin E with their
regular diets for four
weeks before performing
mild fluid percussion
injury (FPI). The Vitamin E
counter reacted against the
effects of fluid
percussion injury.

Vitamin E
supplementation
diet counteracts the
molecular
substrates
underlying
synaptic plasticity
and cognitive
function in the
hippocampus.

Experimental
study in mice

The relationship between
Vitamin E was observed
with protein oxidation
in mice.

Protein oxidation
and nitration
increased in MCI.

The effect of Vitamin E
against a high-fat high
carbohydrate diet (HFCD)

Intrument
Used to Screen
Dementia

Conclusions

Not Applicable

Vitamin E dietary
supplementation
can protect the
brain against the
effects of mild TBI
on synaptic
plasticity and
cognition. Declines
rate of cognitive
impairment.

Not Applicable

The study
suggested that the
therapeutic role of
vitamin E should
be explored in MCI.

Probably Vitamin E
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Table A1. Cont.
Authors

McDougall
et al.

Nesari et al.

Mehrabadi
& Sadr

Iuliano et al.

Whitehair
et al.

Year

2017

2019

2020

2010

2010

Intrument
Used to Screen
Dementia

Conclusions

Not Applicable

Study proves that
vitamin E plays
important role in
protecting
cognitive delay.

Experimental
study on rats

The effect of
Alpha-tocopherol was
evaluated in view of
observing its protective
effect on long-term
memory impairment.

The
Alpha-tocopherol
reduced the passive
avoidance memory
performance,
increased the
level of
malondialdehyde
(MDE) and reactive
oxygen specifies.

Not Applicable

Alphatocopherol was
found to have a
neuroprotective
effect on memory
impairment.

Experimental
study on rats

The effect of vitamins D3
and E, in a combination of
both, was observed on
learning and memory. 60
rats received different
doses of vitamins.

Memory and
learning were
measured by the
Novel Object
Recognition (NOR)
test found to
improve in the rat
group that received
vitamin E.

Not Applicable

Vitamin E can
improve learning
and memory.

Case-control,
experimental
research

An enzymatic relationship
between oxysterols
(24S-hydroxycholesterol
and 27 hydroxycholesterol,
free radical related
oxysterols of oxidative
stress and Vitamin E were
compared between 37
patients of Alzheimer’s
disease, 24 MCI, 29
multi-domains (md-MCI).

People with mild
cognitive
impairment with
oxidative stress
found to be lower
in Vitamin E.

Mini Mental
State
Examination,
Mental
Deterioration
Battery (MDB)

Vitamin E might
have some role in
reducing
oxidative stress
delay and
cognitive delay.

Mini Mental
State
Examination,
Alzheimer’s
Disease
Assessment
Scale-Cognitive
subscale
(ADAS-cog)

A direct
connection
between Vitamin
E and the decline
of cognitive
function could
not be found.
However, the
active status of
APOE ε4 was
found associated
with a fast decline
in cognitive
function.

Study Type

Animal
experimental
study

Experimental
research
design

Sample Characteristics

Findings

The study examined
learning and memory
impairment in zebrafish
with vitamin E deficient
and sufficient.Zebrafish
fed with vitamin E for 45
days acquired sufficient
vitamin E levels.

Learning ability
was observed in
association with
vitamin E level by
excluding the effect
of avoidance
conditioning and
non-associative
learning. Zebrafish
with low vitamin E
were found
learning impaired.

The relationship of
Apolipoprotein E ε4
(APOE ε4) allele was
observed for 36 months of
the period in 516 MCI
patients age between 55 to
90 years who were on
Vitamin E in 516 MCI
participants aged 55–90
years who received
placebo.

Vitamin E did not
find to be
associated with the
progression of
Apolipoprotein
E ε4.
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Table A1. Cont.
Authors

Study Type

Sample Characteristics

Findings

Intrument
Used to Screen
Dementia

Conclusions

Clinical study

This study examined the
relationship between 8
natural compounds of
Vitamin E with cognitive
impairment. 166 MCI
subjects were compared
with cognitively
normal people.

Low plasma
tocopherols and
tocotrienols levels
of vitamin E were
found with
increased odds of
MCI in people
with ID.

The Folstein
Mini-Mental
State
Examination
(MMSE),
Clinical
dementia rating
scale and
Hachinski
ischemic scale

Vitamin E may
have a role
against the
progression of
MCI to AD.

Cohort
research
design

140 non-cognitively
impaired people were
observed for 8 years. The
baseline serum vitamin E
and cognitive impairment
were observed.

The risk of
cognitive
impairment was
found lower among
those who had a
moderate level of
tocopherol/
cholesterol ratio
than those who had
the lowest level of
tocopherols.

Mini-Mental
State
Examination
(MMSE)

Vitamin E might
play an important
role in cognitive
impairment in
humans. Vitamin
E’s therapeutic
role should be
explored.

Crosssectional.

The relationship between
MCI and Vitamin A and E
was explored in a total of
333 participants age
60 years and above.

Vitamin E level was
found lower in
APOEe4 carriers
that affect MCI.

The Folstein
Mini-Mental
State
Examination
(MMSE)

The role of
vitamin E needs
to be further
explored in
relation to MCI.

Double-blind,
placebocontrolled,
parallelgroup,
randomized
clinical trial

The effect of vitamin E on
the progression of
cognitive impairment was
examined. 613 patients
were recruited.
They received either
2000 IU/d of
alpha-tocopherol (n = 152),
20 mg/d of memantine
(n = 155), the combination
(n = 154), or placebo
(n = 152).

Activities of Daily
Living
(ADCS-ADL)
Inventory score
declined in the
group that was
given vitamin E.

Activities of
Daily Living
(ADCS-ADL)
Inventory score,
Mini-Mental
State
Examination
(MMSE)

Vitamin E can
slow down the
progression of
cognitive
impairment.

2014

Prospective
cohort

The effect of vitamin E in
improving cognition in
people diagnosed with
MCI was assessed.
104 people about 70 years
old were included in the
research.

Vitamin E as a
supplementary
dietary found to be
counteractive to
cognitive
impairment.

Alzheimer’s
Disease
Assessment
Scale-Cognitive
subscale
(ADAS-cog)

Vitamin E may
have a role in
lowering the risk
of MCI.

2014

Double-blind
randomized,
placebocontrolled
trial

256 elderly, ages between
65 to 75 were received
300 mg vitamin E with
400 mg of vitamin C or
placebo for 1 year

Vitamin E
reduced the
malondialdehyde
level and raised
total antioxidant
capacity and
glutathione.

Mini-Mental
State
Examination
(MMSE)

Vitamin E
supplementation
did not appear to
be enhancing
cognitive
performance

Year

Mangialasche
2012
et al.

Mangialasche
2013
et al.

Shahar et al.

Dysken
et al.

Zanotta,
Puricelli &
Bonoldi

Naeini et al.

2013

2014
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Table A1. Cont.
Authors

Li et al.

De
Beaumont
et al.

Year

2015

2016

Basambombo
2017
et al.

Liu et al.

Edmonds
et al.

2018

2018

Study Type

Prospective
cohort

Experimental
research

Cohort
research
design

Randomized
controlled
study

Experimental
research
design

Sample Characteristics

Findings

Intrument
Used to Screen
Dementia

Conclusions

This study examined the
effect of vitamin E and C
together and both vitamins
independently on
cognitive functions in the
elderly population.
276 elderly people received
Vitamin E and C together
and E independently.

Radioimmunoassay
(RIA) results,
MMSE, and HDS
assessments
indicated
improvement in
cognitive functions
with vitamin E and
also when vitamin
E was given in
combination with
Vitamin C.

Mini-mental
state
examination
and Hasegawa
Dementia Scale

Vitamin E can
improve
cognitive
functions in the
elderly
population.

The relationship of
apolipoprotein E4
(APOE-ε4) gene and
butyryl cholinesterase
(BCHE) was assessed on
the effect of cognitive
impairment.

The study did not
mention vitamin E;
however, it was
designed on the
premise of that
lower levels of
vitamin E increases
apolipoprotein E4
(APOE-ε4) and
butyryl
cholinesterase
(BCHE) activity
that increases
declines memory.

histopathological
Vitamin E may
confirmation of
have a role in
AD according
lowering the rate
to NINCDSof memory
ADRDA
impairment.
criteria

The effect of Vitamin E and
also Vitamin C was
observed in a cohort of
5269 individuals aged
65 years and above in the
Canadian Study of Health
and Aging (1991–2002).

The baseline
memory and
learning ability
were compared on
the same
standardized tests.
Vitamin E and C
together and
independently
were found to be
associated with a
lower risk of
memory decline.

A randomized controlled
study in 7781 individuals
of European descent.

The effect of donepezil and
Vitamin E was compared
for 756 MCI participants.

Modified
Mini-Mental
State (3MS)
Examination.

Vitamin E plays a
role in reducing
the risk of
memory decline
in individuals.

No association was
observed between
dietary
supplementation of
vitamin E with
cognitive
impairment.

Not available,
since this study
utilized
biomarkers

The study
suggests no
association
between
vitamin E
supplementation
and MCI in the
general
population.

The donepezil
treatment group
had a lower rate of
progression from
MCI to AD than the
Vitamin E group.

The Wechsler
Memory
Scale–Revised
Logical
Memory II
subtest,
Mini-mental
state
examination.

Vitamin E may
not have an effect
on lowering the
rate of MCI
towards AD.
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Table A1. Cont.
Authors

Kim et al.

Casati et al.

Year

2018

2019

Study Type

Sample Characteristics

Findings

Crosssectional

The effect of serum
vitamin A, C, and E was
evaluated for the risk of
cognitive impairment in
230 participants aged 60 to
79 years.

Association
between vitamin A
and C serum was
not observed while
a negative
relationship
between vitamin E,
beta-gamma
tocopherol was
observed with a
lower risk of
cognitive
impairment.

Experimental
research
design

The relationship between
Vitamin E forms and
leukocyte telomere length
(LTL) in AD was explored
for the purpose of
knowing its effect on MCI.
Vitamin E forms (α-, β-, γand δ-tocopherol, α-, β-, γand δ-tocotrienol), the ratio
of α-tocopherylquinone/αtocopherol and
5-nitro-γ-tocopherol/γtocopherol (markers of
oxidative/nitrosative
damage) and LTL were
measured in 53 AD
subjects and 40 cognitively
healthy controls (CTs).

People suffering
from AD found to
have lower
concentrations of
α-, β-, γ- and
δ-tocopherol, αand δ-tocotrienol,
total tocopherols,
total tocotrienols,
and total vitamin E
compared to CTs.

Intrument
Used to Screen
Dementia

Conclusions

Korean version
of the
Mini-Mental
State
Examination

Serum
beta-gamma
tocopherol levels
tended to be
inversely
associated with
the risk of
cognitive
impairment.

Not available,
since this study
utilized
telomere length
as an indicator

The study
suggests that
Vitamin E
deficiency may be
playing a role in
AD pathology in
progressing MCI
to AD.
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